Abstract:Thymosin alpha 1 (Tα1) is a highly conserved 28 amino-acid peptide naturally occurring in the thymus and plays critical roles in T cell maturity and differentiation. Its synthetic form, thymalfasin, has been approved by various regulatory agencies in the treatment of hepatitis B viral infection and as an enhancer of vaccine response in immune-compromised populations. In China, it has also widely utilized in patients with cancer and severe infections, as well as the emergency use during (Severe Acute Respiratory Syndrome)SARS and COVID-19 pandemic as an immune-regulator. Recent studies showed that Tα1 could significantly improve overall survival (OS) in patients with surgically resectable non-small cell lung cancer (NSCLC) and liver cancers in the adjuvant setting. For patients with locally advanced, unresectable NSCLC, Tα1 could significantly reduce chemoradiation-induced lymphopenia, pneumonia, and trending improvement of OS. Preclinical evidence are emerging to demonstrate that Tα1 may augment efficacy of cancer chemotherapy by reversing efferocytosis-induced M2 polarization of macrophages via activation of a TLR7/SHIP1 axis and enhancing anti-tumor immunity by turning "cold-tumors" to "hot-tumors"; a protective role in reducing colitis caused by immune check-point inhibitors (ICIs). Potential enhancement of ICIs' clinical efficacies has also been indicated. ICIs have transformed ways treating patients with cancer but limitations such as relatively low response rates and certain safety issues remains. Given the roles of Tα1 in regulating cellular immunities and exceptional safety profiles demonstrated in decades clinical uses, we believe that it is plausible to explore implications of Tα1 the immune-oncology setting by combining with ICI-based therapeutic strategies. Background Activities of Tα1. Tα1 is a biological response modifier which activates various cells in the immune system [1-3]. Tα1 is therefore expected to have clinical benefits in disorders where immune responses are impaired or ineffective. These disorders include acute and chronic infections, cancers, and vaccine non-responsiveness. In severe sepsis, for example, sepsis-induced immunosuppression is increasingly recognized as the overriding immune dysfunction in these vulnerable patients [4] and there is now agreement that many patients with severe sepsis survive the first critical hours of the syndrome but eventually die later due to patients' immunosuppression which make the system difficulty to fight the primary bacterial infection, decreased resistance to secondary nosocomial infections, and reactivation of viral infections [5]. Tα1 has been shown to restore immune functions and help to reduce mortality in patients with severe sepsis.

Study on the Expression of Thymosin α1(Tα1) Protein in S180 of Mice with Immunohistolchemical Method

Effect of Thymosin Alpha 1 on Cellular Immune Function in Elderly Patients with Malignant Tumor

Thymosin Α-1 in Cancer Therapy: Immunoregulation and Potential Applications

Special Expression of Thy-1 in Different Malignant Tumors

Immunomodulatory Function of Orally Administered Thymosin Α1

IMMUNOHISTOCHEMICAL ANALYSIS OF THE EXPRESSION OF S-100 PROTEIN IN THYMUSES OF PRE- AND POST-NATAL MICE

Expression of Transforming Growth Factor Β1 in Gastric Cancer and Its Clinical Value

The Clinical Study of Thymosinα1 Therapeutic Effect of Chemotherapy in Advanced Gastric Cancer

[Construction of Eukarocyte Expression Recombinant of Human Thymosin Alpha1 and Its Influnce to Immune Activity of PBLs Transfected with the Recombinant Pbk-T Alpha1]

Expression of Bioactive Thymosin Α1 Using Marker Free Transgenic Tobacco.

The Effect of Thymosin Alpha 1 on Expression Profiles of Signal Transductors Involving Anti-Infection in Human Lymphocytes

A Reappraisal of Thymosin Alpha1 in Cancer Therapy

Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]

A Modified Thymosin Alpha 1 Inhibits the Growth of Breast Cancer Both in Vitro and in Vivo: Suppressment of Cell Proliferation, Inducible Cell Apoptosis and Enhancement of Targeted Anticancer Effects

Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer

Research on the Significance of Thymosin Α1 for Infection Risk and Prognosis in Elderly Lung Cancer Patients Received Chemotherapy

Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era

Thymosin β4 expression in human tissues and in tumors using tissue microarrays

The expression and clinical signiifcance of Stanniocalcin-1 in breast cancer

Preliminary study on protein and mRNA expressions of S1P1 and AT1R in human liver cancer tissues

Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life